Illing B, Horn M, Han H, Hahn S, Bureik P, Ertl G, Neubauer S
Medizinische Universitätsklinik, Würzburg, Germany.
J Cardiovasc Pharmacol. 1996 Apr;27(4):487-94. doi: 10.1097/00005344-199604000-00006.
Endothelin-1 (ET-1) has been suggested to be involved in the pathophysiology of ischemia/reperfusion injury, but direct proof for this is still sparse. We tested whether protection of high-energy phosphate metabolism contributes to the beneficial effects of ETA receptor antagonists during ischemia/reperfusion. In isolated, buffer-perfused rat hearts, isovolumic function was measured by a left ventricular (LV) balloon, and 31P nuclear magnetic resonance spectra were continuously recorded. Two protocols were performed: (a) 15-min control, 30-min total, global ischemia, and 15-min reperfusion; and (b) 15-min control, 15-min total, global ischemia, and 30-min reperfusion. Treatment with BQ610 (1.75 micrograms/min) or saline was started during control and continued throughout the protocol. BQ610 did not affect function or energy metabolism under control conditions. In BQ610-treated hearts subjected to 30-min ischemia, time to ischemic contracture was significantly delayed (treated 10.6 +/- 0.4 min; untreated 8.1 +/- 0.7 min), and end-diastolic pressure (EDP) remained lower (after 30-min ischemia 26 +/- 2 vs. 35 +/- 2 mm Hg). In addition, recovery of mechanical function in BQ610-treated hearts was accelerated during reperfusion. BQ610 did not affect ATP but significantly accelerated and increased creatine phosphate (51 +/- 7 vs. 37 +/- 3%) recovery on reperfusion after 30-min ischemia. BQ610-treated hearts subjected to 15-min ischemia also showed lower EDP during ischemia and accelerated recovery of mechanical function during reperfusion. However, in this case, there were no differences in high-energy phosphate concentrations between treated and untreated hearts. We conclude that the protective action of BQ610 on mechanical function during ischemia/reperfusion injury can be but is not consistently associated with beneficial effects on cardiac high-energy phosphate metabolism.
内皮素 -1(ET -1)被认为与缺血/再灌注损伤的病理生理学有关,但对此的直接证据仍然稀少。我们测试了高能磷酸代谢的保护作用是否有助于ETA受体拮抗剂在缺血/再灌注期间产生有益效果。在离体的、缓冲液灌注的大鼠心脏中,通过左心室(LV)球囊测量等容功能,并连续记录31P核磁共振谱。进行了两个方案:(a)15分钟对照、30分钟全心整体缺血和15分钟再灌注;(b)15分钟对照、15分钟全心整体缺血和30分钟再灌注。在对照期间开始用BQ610(1.75微克/分钟)或生理盐水治疗,并在整个方案中持续。BQ610在对照条件下不影响功能或能量代谢。在接受30分钟缺血的BQ610治疗的心脏中,缺血性挛缩的时间显著延迟(治疗组10.6±0.4分钟;未治疗组8.1±0.7分钟),舒张末期压力(EDP)仍然较低(30分钟缺血后26±2与35±2毫米汞柱)。此外,BQ610治疗的心脏在再灌注期间机械功能的恢复加速。BQ610不影响ATP,但在30分钟缺血后的再灌注时显著加速并增加了磷酸肌酸的恢复(51±7与37±3%)。接受15分钟缺血的BQ610治疗的心脏在缺血期间也显示出较低的EDP,并且在再灌注期间机械功能恢复加速。然而,在这种情况下,治疗组和未治疗组的心脏之间高能磷酸盐浓度没有差异。我们得出结论,BQ610在缺血/再灌注损伤期间对机械功能的保护作用可以但并非始终与对心脏高能磷酸代谢的有益作用相关。